Buscar
EyePoint Pharmaceuticals Inc
EYPTAñadir a la lista de seguimiento
4.250USD
+0.020+0.47%
Cierre 09-11 16:00（ET）
361.17MCap. mercado
PérdidaP/E TTM
Más Datos de EyePoint Pharmaceuticals Inc Compañía
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Perfil de EyePoint Pharmaceuticals Inc
Símbolo de cotizaciónEYPT
Nombre de la empresaEyePoint Pharmaceuticals Inc
Fecha de salida a bolsaJan 27, 2005
Director ejecutivoDuker (Jay S)
Número de empleados165
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 27
Dirección480 Pleasant Street, Suite C400
CiudadWATERTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02472
Teléfono16179265000
Sitio Webhttps://eyepointpharma.com/
Símbolo de cotizaciónEYPT
Fecha de salida a bolsaJan 27, 2005
Director ejecutivoDuker (Jay S)
Ejecutivos de EyePoint Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
175.21K
+6.05%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
175.21K
+6.05%
Ms. Wendy F. DiCicco, CPA
Ms. Wendy F. DiCicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
137.46K
+21.85%
Ms. Wendy F. DiCicco, CPA
Ms. Wendy F. DiCicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
137.46K
+21.85%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
952.69K
+0.90%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Director
Non-Executive Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
175.21K
+6.05%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de EyePoint Pharmaceuticals Inc?
Los cinco principales accionistas de EyePoint Pharmaceuticals Inc son: Dr. Jay S. Duker, M.D.
¿Cuántas instituciones poseen acciones de EyePoint Pharmaceuticals Inc (EYPT)?
A fecha de 2026Q1, 381 instituciones poseen acciones de EyePoint Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 88.53M, lo que representa el 105.59% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2754490.00.
¿Cuál es la mayor fuente de ganancias de EyePoint Pharmaceuticals Inc?
El 2026Q1, el segmento empresarial YUTIQ generó la ganancia más alta para EyePoint Pharmaceuticals Inc, ascendiendo a 1.60M y representando el 5.10% de la ganancia total.